recaticimab + adebrelimab

A combination regimen consisting of **recaticimab** and **adebrelimab**, used in investigational protocols as a perioperative or palliative treatment for certain solid malignancies, notably non-small cell lung cancer and metastatic biliary tract carcinoma. - **Recaticimab** is a fully human monoclonal antibody that targets PCSK9 (proprotein convertase subtilisin/kexin type 9), leading to increased LDL receptor expression and substantial reduction in low-density lipoprotein cholesterol (LDL-C). It is being explored for additional benefits in cancer due to potential immune effects associated with PCSK9 inhibition. - **Adebrelimab** is a humanized IgG1 monoclonal antibody that inhibits PD-L1 (programmed death-ligand 1), blocking its immunosuppressive interaction with PD-1 and B7.1 receptors and thereby enhancing antitumor immune responses, fitting the immunotherapy category as an immune checkpoint inhibitor. The combination is under investigation for synergistic effects, as inhibition of PCSK9 may enhance immune infiltration and responsiveness to immune checkpoint blockade, resulting in more effective and enduring anti-tumor activity.